Literature DB >> 20610822

The changing epidemiology of Clostridium difficile infections.

J Freeman1, M P Bauer, S D Baines, J Corver, W N Fawley, B Goorhuis, E J Kuijper, M H Wilcox.   

Abstract

The epidemiology of Clostridium difficile infection (CDI) has changed dramatically during this millennium. Infection rates have increased markedly in most countries with detailed surveillance data. There have been clear changes in the clinical presentation, response to treatment, and outcome of CDI. These changes have been driven to a major degree by the emergence and epidemic spread of a novel strain, known as PCR ribotype 027 (sometimes referred to as BI/NAP1/027). We review the evidence for the changing epidemiology, clinical virulence and outcome of treatment of CDI, and the similarities and differences between data from various countries and continents. Community-acquired CDI has also emerged, although the evidence for this as a distinct new entity is less clear. There are new data on the etiology of and potential risk factors for CDI; controversial issues include specific antimicrobial agents, gastric acid suppressants, potential animal and food sources of C. difficile, and the effect of the use of alcohol-based hand hygiene agents.

Entities:  

Mesh:

Year:  2010        PMID: 20610822      PMCID: PMC2901659          DOI: 10.1128/CMR.00082-09

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  196 in total

1.  Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting.

Authors:  D G Levy; A Stergachis; L V McFarland; K Van Vorst; D J Graham; E S Johnson; B J Park; D Shatin; J C Clouse; G W Elmer
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

2.  Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors:  F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Authors:  S Johnson; M H Samore; K A Farrow; G E Killgore; F C Tenover; D Lyras; J I Rood; P DeGirolami; A L Baltch; M E Rafferty; S M Pear; D N Gerding
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

Review 4.  Antibiotics and Clostridium difficile.

Authors:  J Freeman; M H Wilcox
Journal:  Microbes Infect       Date:  1999-04       Impact factor: 2.700

5.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

6.  Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Authors:  Annie-Claude Labbé; Louise Poirier; Duncan Maccannell; Thomas Louie; Michel Savoie; Claire Béliveau; Michel Laverdière; Jacques Pépin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

7.  Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile.

Authors:  Nathalie Vernaz; Hugo Sax; Didier Pittet; Pascal Bonnabry; Jacques Schrenzel; Stephan Harbarth
Journal:  J Antimicrob Chemother       Date:  2008-05-08       Impact factor: 5.790

8.  Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006.

Authors:  H Martin; B Willey; D E Low; H R Staempfli; A McGeer; P Boerlin; M Mulvey; J S Weese
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

9.  Metronidazole resistance in Clostridium difficile is heterogeneous.

Authors:  T Peláez; E Cercenado; L Alcalá; M Marín; A Martín-López; J Martínez-Alarcón; P Catalán; M Sánchez-Somolinos; E Bouza
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

10.  Clindamycin-resistant clone of Clostridium difficile PCR Ribotype 027, Europe.

Authors:  Denise Drudy; Bram Goorhuis; Dennis Bakker; Lorraine Kyne; Renate van den Berg; Lynda Fenelon; Seamus Fanning; Edward J Kuijper
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

View more
  290 in total

1.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

2.  Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota.

Authors:  Mary C Rea; Orla O'Sullivan; Fergus Shanahan; Paul W O'Toole; Catherine Stanton; R Paul Ross; Colin Hill
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.

Authors:  Judith M Wenisch; Daniela Schmid; Hung-Wei Kuo; Franz Allerberger; Verena Michl; Philip Tesik; Gerhard Tucek; Hermann Laferl; Christoph Wenisch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 4.  Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded.

Authors:  Tze S Khor; Hiroshi Fujita; Koji Nagata; Michio Shimizu; Gregory Y Lauwers
Journal:  J Gastroenterol       Date:  2012-02-10       Impact factor: 7.527

5.  An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype.

Authors:  Warren N Fawley; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

Review 6.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

7.  Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Authors:  Larry K Kociolek; Dale N Gerding; David W Hecht; Egon A Ozer
Journal:  Microbes Infect       Date:  2018-01-31       Impact factor: 2.700

8.  Identification and characterization of glycoproteins on the spore surface of Clostridium difficile.

Authors:  Philippa C R Strong; Kelly M Fulton; Annie Aubry; Simon Foote; Susan M Twine; Susan M Logan
Journal:  J Bacteriol       Date:  2014-05-09       Impact factor: 3.490

9.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

10.  Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.

Authors:  A Lo Vecchio; L Lancella; C Tagliabue; C De Giacomo; S Garazzino; M Mainetti; L Cursi; E Borali; M V De Vita; E Boccuzzi; L Castellazzi; S Esposito; A Guarino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.